Company / Cost of Revenue
PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$114.2M
FY2025
5-year range
$71.7M / $147.7M
FY2021-FY2025
Trend
-2.1%
vs FY2024
Sector context
#88 of 113
Health Care
What the data says
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s cost of revenue of $114M is lower than 78% of companies in the Health Care sector (FY2025). Cost of Revenue has fluctuated over the past 10 years, ranging from $46M in FY2020 to $148M in FY2023.
Based on SEC 10-K filings.
$114M in FY2025 with a 5-year CAGR of +19.8%.
Improved from $148M to $114M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +12.9%
- 5-Year CAGR
- +19.8%
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 113This company $114.2M Sector average $11.3B
▼
-99.0% below sector average
Key checks
Key Insights
- 5-year CAGR of +19.8%, indicating consistent growth.
- In FY2025, cost of revenue decreased 2.1% year-over-year.
- Ranks #88 out of 113 companies in the Health Care sector.
- Peak cost of revenue was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $114.2M | -2.1% |
| FY2024 | $116.7M | -21.0% |
| FY2023 | $147.7M | +86.4% |
| FY2022 | $79.3M | +10.6% |
| FY2021 | $71.7M | +54.7% |
| FY2020 | $46.3M | -17.7% |
| FY2019 | $56.3M | +5.2% |
| FY2018 | $53.5M | -9.0% |
| FY2017 | $58.8M | +26.3% |
| FY2016 | $46.6M | +113.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026